Experienced in Serum Sickness

Emanuele Bosi

Milan, IT 
Experienced in Serum Sickness
Milan, IT 
OverviewLocationsClinical Research

Overview

Emanuele Bosi practices in Milan, Italy. Mr. Bosi is rated as an Experienced expert by MediFind in the treatment of Serum Sickness. His top areas of expertise are Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), Low Blood Sugar, Adiposis Dolorosa, and Pancreas Transplant.

His clinical research consists of co-authoring 172 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Serum Sickness.

Gender
Male

Locations

Milan, Italy
Other Locations
Genoa, Italy
Palermo, Italy
Pisa, 56126, Italy
Florence, Italy
Sesto Fiorentino, Italy
Italy
Via Madonna Del Piano 6, Sesto San Giovanni, 50019, Italy
Rome, 00161, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
Enrollment Status: Completed
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drug: Anti-Human Thymocyte Immunoglobulin, Rabbit
Study Phase: Phase 2
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)
Enrollment Status: Active_not_recruiting
Publish Date: October 30, 2024
Intervention Type: Drug
Study Drug: Verapamil SR
Study Phase: Phase 2
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes
Enrollment Status: Completed
Publish Date: April 19, 2024
Intervention Type: Drug
Study Phase: Phase 2
Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D)
Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D)
Enrollment Status: Terminated
Publish Date: April 09, 2024
Intervention Type: Drug
Study Drug: Hydroxychloroquine
Study Phase: Phase 2
A Monocentric, Open-label Pilot Study to Assess the Safety and Efficacy of Minimal Islet Transplantation in Patients With New-onset Type 1 Diabetes
A Monocentric, Open-label Pilot Study to Assess the Safety and Efficacy of Minimal Islet Transplantation in Patients With New-onset Type 1 Diabetes
Enrollment Status: Completed
Publish Date: February 22, 2024
Intervention Type: Drug, Biological
Study Drugs: Human pancreatic islet, ATG, Pegylated G-CSF, Rapamycin
Study Phase: Phase 2
Evaluation of the Efficacy of Rapamycin and a Dipeptidyl Peptidase-4 Inhibitor (Vildagliptin) in Improving Beta Cell Function in Type 1 Diabetes of Long Duration, a Perspective Randomized Study
Evaluation of the Efficacy of Rapamycin and a Dipeptidyl Peptidase-4 Inhibitor (Vildagliptin) in Improving Beta Cell Function in Type 1 Diabetes of Long Duration, a Perspective Randomized Study
Enrollment Status: Completed
Publish Date: November 04, 2020
Intervention Type: Drug
Study Phase: Phase 2
Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes
Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: January 21, 2020
Intervention Type: Device
Study Phase: Not Applicable
View 6 Less Clinical Trials

172 Total Publications

Functional recovery of islet β cells in human type 2 diabetes: Transcriptome signatures unveil therapeutic approaches.
Functional recovery of islet β cells in human type 2 diabetes: Transcriptome signatures unveil therapeutic approaches.
Journal: Science advances
Published: October 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bosi's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile